JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
The trial will evaluate pharmacodynamics,pharmacokinetics,safety,and efficacy of JMKX000189 versus placebo in participants with moderately to severely active systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment.
Epistemonikos ID: 122bc48a862f274d9422d3b16e2c5d89dc5d370b
First added on: May 15, 2024